$23.4M in CY2024 Part D spend10K claims · 4K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tocilizumab-Aazg used for?
Tocilizumab-Aazg is a Interleukin-6 Receptor Antagonist medication tracked in Medicare Part D.
Is there a generic for Tocilizumab-Aazg?
No. Tocilizumab-Aazg is brand-only with no generic equivalents currently in market.
How much does my plan pay for Tocilizumab-Aazg?
Across 329 Part D plans, Tocilizumab-Aazg averages $821.71/unit (NADAC). Lowest available: $821.71/unit. Highest in distribution: $821.71/unit.
Is Tocilizumab-Aazg on the FDA shortage list?
No. Tocilizumab-Aazg is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.